Clinical Trial Update: Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib in metastatic solid tumors that progressed after standard therapy has completed, with multiple indicated cancers explored.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Ovarian Cancer
• Pancreatic Cancer
• Sarcoma
• Thymic Carcinoma
• Thymoma Type B2
• Thymoma Type B3

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Pancreas Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED